Cortexyme Company
Cortexyme is developing treatments for Alzheimer's and other degenerative disorders.
Investment Stage:
N/A
Founded Date:
2012
Investor Type:
N/A
Estimated Revenue:
$10M to $50M
Total Funding:
225000000
Investors Number:
13
Employee Number:
11-50
Number Of Exists:
N/A
Last Funding Type:
Post-IPO Equity
Industry:
Biotechnology, Health Care, Medical, Pharmaceutical
Technology:
Gene therapy
Headquarters:
South San Francisco, California, United States
Funding Status:
IPO
Last Funding Date:
2019